CC
INDV icon

Centiva Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Centiva Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85,090
Closed -$830K – 2017
2024
Q3 		$830K Buy
85,090
+60,090
+240% +$704K 0.02% 963
2024
Q2 		$403K Buy
25,000
+9,840
+65% +$178K 0.01% 1294
2024
Q1 		$325K Buy
+15,160
New +$285K 0.01% 1204

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Centiva Capital's INDV Position: Q4 2024 in Review

Centiva Capital sold out of Indivior Pharmaceuticals (INDV) in Q4 2024, closing a stake of 85,090 shares — an estimated $830K sold.

Centiva Capital first reported a position in INDV in Q1 2024 and held it in 3 quarters. The position peaked at $830K in Q3 2024. 113 funds tracked by Wall St. Rank hold INDV as of Q4 2024.

  • Centiva Capital reported no remaining Indivior Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 85,090 Indivior Pharmaceuticals shares in Q4 2024, an estimated $830K.
  • Centiva Capital first reported a position in Indivior Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Centiva Capital's Indivior Pharmaceuticals position peaked at $830K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.